InfoSynergy
Berberine
Berberine may add modest lipid-lowering effects to Bempedoic Acid.
Recommendation: Use as part of the lipid plan, not as a substitute for prescribed therapy; recheck lipids after regimen changes.
Bempedoic Acid
Prescription ·Strong evidence ·Reviewed May 2026
Bempedoic acid is an oral, once-daily ATP-citrate lyase (ACL) inhibitor used to lower LDL cholesterol, typically as an add-on to maximally tolerated statins or in statin-intolerant patients. It is a prodrug activated primarily in the liver, which limits muscle-related side effects seen with statins. It can be combined with ezetimibe in a fixed-dose product and has been shown to reduce major cardiovascular events in statin-intolerant patients.
What it's good for
- Lowering LDL cholesterol in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia)1,2
- Add-on therapy to maximally tolerated statins when additional LDL lowering is needed2
- LDL lowering in patients who are statin-intolerant1,2
- Reducing the risk of major adverse cardiovascular events in statin-intolerant patients with or at high risk for cardiovascular disease1,3
What to watch for
- Elevated uric acid (hyperuricemia) and gout flares
- Upper respiratory tract infection
- Muscle spasms
- Known hypersensitivity to bempedoic acid or any component of the formulation1,2
- Use caution and consider statin dose limits because bempedoic acid increases plasma concentrations of simvastatin and pravastatin (avoid simvastatin doses above 20 mg and pravastatin doses above 40 mg when used together)1,2
The bottom line
Evidence rating strong. Most-documented uses: lowering ldl cholesterol in adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia), add-on therapy to maximally tolerated statins when additional ldl lowering is needed, ldl lowering in patients who are statin-intolerant. 3 sources indexed (2016–2023), with 6 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
Bempedoic acid is a prodrug that is converted to its active form (bempedoyl-CoA) by the enzyme very long-chain acyl-CoA synthetase 1 (ACSVL1), which is expressed in the liver but not in skeletal muscle. The active metabolite inhibits ATP-citrate lyase (ACL), an enzyme that acts upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Inhibiting ACL reduces hepatic cholesterol synthesis, leading to upregulation of LDL receptors and increased clearance of LDL particles from the blood. Because the activating enzyme is essentially absent in muscle tissue, bempedoic acid does not produce active drug in muscle, which accounts for its low rate of myalgia compared with statins.3,1
Class
Lipid-lowering agent (ATP-citrate lyase inhibitor)
Dosing
Dosing & protocol.
Common range
180 mg orally once daily, with or without food. Available alone or as a fixed-dose combination with ezetimibe 10 mg.
Recommended form
Oral tablet (180 mg), taken once daily
Can be taken with or without food at any time of day; food does not meaningfully affect efficacy. It is a prodrug activated in the liver. Bile-acid sequestrants and some other drugs may affect absorption if dosed together, so separate administration is generally advised.
Safety
Full safety detail.
Side effects
- Elevated uric acid (hyperuricemia) and gout flares
- Upper respiratory tract infection
- Muscle spasms
- Back pain
- Abdominal pain or discomfort
- Increased liver enzymes (transaminase elevations)
- Increased blood creatinine and decreased estimated GFR
- Tendon rupture (uncommon; higher risk with concurrent fluoroquinolones, corticosteroids, renal impairment, or in patients over 60)
- Anemia and elevated platelet counts (reported in trials)
Contraindications
- Known hypersensitivity to bempedoic acid or any component of the formulation1,2
- Use caution and consider statin dose limits because bempedoic acid increases plasma concentrations of simvastatin and pravastatin (avoid simvastatin doses above 20 mg and pravastatin doses above 40 mg when used together)1,2
- Pregnancy and breastfeeding are generally not recommended for lipid-lowering therapy of this type2
- History of gout or hyperuricemia warrants caution due to risk of elevated uric acid2
- History of tendon disorders or tendon rupture warrants caution
Interactions
Interaction records.
InfoSynergy
Psyllium Husk
Psyllium Husk may add modest lipid-lowering effects to Bempedoic Acid.
Recommendation: Use as part of the lipid plan, not as a substitute for prescribed therapy; recheck lipids after regimen changes.
InfoSynergy
Fish Oil
Bempedoic acid lowers LDL cholesterol via inhibition of ATP-citrate lyase, while prescription-grade omega-3 fatty acids (especially icosapent ethyl) primarily lower triglycerides and, in high-risk patients, reduce cardiovascular events. The two are commonly used together as part of a comprehensive lipid-lowering strategy, often alongside or as an alternative to statins. There is no pharmacokinetic conflict, and the lipid-lowering and triglyceride-lowering effects are complementary rather than overlapping.
Recommendation: Combining fish oil (or prescription omega-3s) with bempedoic acid is reasonable for patients who need both LDL and triglyceride control. Use this combination as directed by the prescriber and continue to monitor a full lipid panel. High-dose fish oil can modestly increase bleeding tendency and, with icosapent ethyl, atrial fibrillation risk, so disclose all supplements to your clinician.
InfoSynergy
Coenzyme Q10
Coenzyme Q10 (ubiquinone) is frequently used by patients on cholesterol-lowering therapy because statins deplete endogenous CoQ10 synthesis. Bempedoic acid acts upstream of the mevalonate pathway at ATP-citrate lyase and, unlike statins, does not directly inhibit HMG-CoA reductase in muscle, so CoQ10 depletion and myopathy are far less of a concern. There is no pharmacokinetic interaction between CoQ10 and bempedoic acid.
Recommendation: CoQ10 can be taken safely alongside bempedoic acid. Its theoretical benefit is smaller than with statins because bempedoic acid is a prodrug activated mainly in the liver and is associated with low rates of muscle symptoms. Continue CoQ10 if it is already part of your regimen, but do not expect it to be necessary for muscle protection on bempedoic acid alone.
InfoSynergy
Garlic Extract
Aged garlic extract produces modest reductions in LDL and total cholesterol and is sometimes used by patients pursuing additional lipid lowering. When combined with bempedoic acid the cholesterol-lowering effects may be additive, with no pharmacokinetic conflict. The clinically relevant caution is that high-dose garlic has mild antiplatelet activity, which is additive with any concurrent antiplatelet or anticoagulant therapy rather than with bempedoic acid itself.
Recommendation: Garlic extract may be combined with bempedoic acid without dose adjustment. If you also take aspirin, clopidogrel, or an anticoagulant, be aware that garlic can mildly increase bleeding risk and should be disclosed to your clinician, particularly before surgery. Garlic's lipid effect is modest and should not replace prescribed therapy.
InfoCaution
Vitamin C
Bempedoic acid can raise serum uric acid by competing with uric acid for renal tubular secretion via OAT2, and gout has been reported as an adverse effect. High-dose vitamin C (typically several grams per day) has a uricosuric effect that lowers serum uric acid. While this could theoretically offset bempedoic-acid-induced hyperuricemia, very high vitamin C intake also increases urinary oxalate and uric acid excretion, which can promote kidney stones in susceptible individuals. The interaction is minor and not a reason to avoid either agent.
Recommendation: Normal dietary or low-dose supplemental vitamin C is fine with bempedoic acid. If you take gram-level vitamin C and have gout, hyperuricemia, or a history of kidney stones, discuss this with your clinician, since both bempedoic acid (raising uric acid) and high-dose vitamin C (increasing urinary uric acid/oxalate) act on renal urate handling. Periodic uric acid monitoring is reasonable while on bempedoic acid.
Sources
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Randomized controlled trials
2- 1Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes trial)Needs reviewPMIDNissen SE, Lincoff AM, Brennan D, et al. · New England Journal of Medicine · 2023
In statin-intolerant patients, bempedoic acid lowered LDL cholesterol and significantly reduced the risk of a composite of major adverse cardiovascular events compared with placebo.
- 2Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol (CLEAR Harmony trial)Needs reviewPMIDRay KK, Bays HE, Catapano AL, et al. · New England Journal of Medicine · 2019
Bempedoic acid reduced LDL cholesterol by approximately 18 percent compared with placebo when added to maximally tolerated statin therapy, with a safety profile generally similar to placebo aside from higher rates of gout and elevated uric acid.
Reference material
1- 3Bempedoic acid: mechanism of action and clinical pharmacologyNeeds reviewPMIDPinkosky SL, Newton RS, Day EA, et al. · Nature Communications · 2016
Bempedoic acid requires activation by very long-chain acyl-CoA synthetase 1, an enzyme absent from skeletal muscle, so it inhibits cholesterol synthesis in the liver via ATP-citrate lyase without generating active drug in muscle.
Keep exploring
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Bempedoic Acid in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.